Together, we reach far beyond the skin
Putting innovation into practice
with an extensive global portfolio of treatments in medical dermatology
Lifting the burden of disease
for nearly 100 million people who rely on our medicines every year
Shaping the future of what’s next
in partnership with healthcare organizations, scientists and patient groups
LEO Pharma delivers 10% revenue growth in 2025 and more than doubles adjusted EBITDA margin
In 2025, LEO Pharma delivered a third consecutive year of double‑digit revenue growth (CER), at the upper end of guidance, and achieved a significant improvement in profitability, returning to positive net profit and free cash flow.
MORE NEWS
- Feb 18 2026 LEO Pharma delivers 10% revenue growth in 2025 and more than doubles adjusted EBITDA margin
- Jan 21 2026 LEO Pharma advances Anzupgo® (delgocitinib) cream to phase 3 trial in lichen sclerosus (LS)
- Jan 07 2026 LEO Pharma to present at the 44th annual J.P. Morgan Healthcare Conference
LEO Pharma delivers 10% revenue growth in 2025 and more than doubles adjusted EBITDA margin
In 2025, LEO Pharma delivered a third consecutive year of double‑digit revenue growth (CER), at the upper end of guidance, and achieved a significant improvement in profitability, returning to positive net profit and free cash flow.
Discover how we innovate collectively.
For us, collaborating innovatively means continuously enhancing and expanding what's achievable for one another, our company, and our patients.